Those who followed the investment forums were able to participate in Optomed’s price increase earlier than those who waited for the stock exchange announcement.
A health technology company Optomedin the investor story has been based on one card. In earnings announcements, the quarterly numbers have received less attention than the management’s comments on how the licensing process for the Aurora AEYE eye fundus camera equipped with artificial intelligence is progressing in the United States.
This week, the US Food and Drug Administration FDA granted permission to sell and market the Aurora AEYE camera in the US. The news is revolutionary for Optomed’s owners, business operations and share price.
It is interesting that information about the FDA approval, which is extremely important to the company, was on private investors’ discussion forums a day before the company was able to announce the matter itself.
Information about the license could basically be found by anyone on the FDA’s open website. No leaks or shady tips from insiders. I don’t know how the information ended up on the forums, but in any case, expertise, wit and keen eye were enough to find it.
After the information spread on Monday, Optomed’s share price rose by around seven percent. On Tuesday, after Optomed announced the matter itself, the price rose by 14 percent. Those who followed the forums were able to join the rise in good time.
The reason behind the delay is that the actual applicant for FDA approval was Optomed’s partner AEYE Health. Optomed was only able to announce the license after receiving confirmation from AEYE Health, even though the information was right in front of the investors’ noses as soon as they knew how to look.
The case is kind of gratifying. Profits are still available on the market with your own work and hookups. Forum investors should be congratulated. The communality of the forums also played its part, when information was interpreted, doubted and believed in turn.
There is also a risk of withdrawal associated with communality. There is always someone who is there to pump up the stock price of the small company with little turnover in the portfolio. The level of conversation varies. In the case of Optomed, the forums were right at the right time.
The FDA approval means that Optomed can start commercializing its camera for the screening of diabetic retinopathy, a comorbidity of diabetes, in the world’s largest market, the United States.
Instead of following the progress of the permit process, investors can start following the progress of Optomed’s business. What impact is the sales organization, which is hopefully already denting in its racks? Can a new type of solution be introduced to the market?
It requires work, but the conditions are certainly there. As diabetes becomes more common, retinopathy also becomes more common and thus the need for regular examination of the fundus, so there should be enough of a market to harvest if the solution is deemed useful.